ArticleFrontiers in oncology2024
Exploration of risk factors and characteristics of COVID-19 infection among patients with hematological malignancies in Suzhou, China: a retrospective study.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ablation-immunotherapy synergy in cancer: mechanisms of the abscopal effect, emerging clinical applications, and translational roadmaps for next-generation onco-immunology.Medical oncology (Northwood, London, England) · 2026Review
- Explainable AI-Assisted Multimodal Ultrasound Radiomics for Preoperative Risk Stratification of Central Lymph Node Metastasis in Papillary Thyroid Carcinoma.Journal of imaging informatics in medicine · 2026Article
- Epigenetic Inhibition of HDAC7 by Daidzein isolated from Macrotyloma uniflorum: A potential therapeutic approach in leukemia in silico, in-vitro and in-vivo.Medical oncology (Northwood, London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim: Patients diagnosed with cancer, particularly those with hematologic malignancies, frequently exhibit a state of immunosuppression. Currently, there remains a scarcity of dependable biomarkers for assessing the severity of COVID-19 in individuals with hematologic malignancies. We conducted a retrospective study of morbidity and mortality in patients with hematological malignancies (HM) who had contracted COVID-19. The aim was to offer a reference for clinical diagnosis and treatment. Methods: A total of 71 patients with HM-confirmed COVID-19 were enrolled from December 2022 to May 2023. Clinical symptoms, laboratory findings, and treatment approaches were collected and documented. Patients were classified into survival and death groups based on their COVID-19 outcomes, and statistical analysis was performed on the clinical data from both groups. Results: Among the 71 patients, 57 (80.3%) were alive, and 14 (19.7%) had died. The mean age of patients in the death group was significantly higher than that of the survival group (51.29 ± 20.76 Conclusion: Patients with hematologic malignancies suffer severe morbidity and mortality due to COVID-19 infection. LDH may serve as a risk factor associated with prognosis in the treatment of COVID-19. Monitoring variations in LDH levels can assist healthcare providers in evaluating disease progression, adjusting treatment plans in a timely manner, and predicting patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.